文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

原发性胶质母细胞瘤的复发模式分析

Recurrence Pattern Analysis of Primary Glioblastoma.

作者信息

Rapp Marion, Baernreuther Jessica, Turowski Bernd, Steiger Hans-Jakob, Sabel Michael, Kamp Marcel A

机构信息

Department of Neurosurgery, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.

Department of Neurosurgery, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.

出版信息

World Neurosurg. 2017 Jul;103:733-740. doi: 10.1016/j.wneu.2017.04.053. Epub 2017 Apr 19.


DOI:10.1016/j.wneu.2017.04.053
PMID:28434963
Abstract

BACKGROUND: Typical recurrence of glioblastoma occurs locally, usually within 2 cm from the original lesion. With improvement of surgical techniques, more aggressive surgical strategies have become feasible, resulting in a significantly increased rate of complete resection. We investigated whether these improvements are also reflected by tumor recurrence pattern. METHODS: Inclusion criteria were first diagnosis of glioblastoma with standard adjuvant radiochemotherapy and histologically proven tumor recurrence. Patients were divided according to recurrence pattern: local recurrence, distant recurrence, or both recurrence patterns. Data were correlated with extent of resection, molecular tumor configuration, clinical status, and survival data. RESULTS: This single-center retrospective study included 97 patients with glioblastoma treated between 2007 and 2014. Local, distant, and combined tumor recurrence patterns were observed in 77 (79.3%), 10 (10.3%), and 10 patients (10.3%). Median progression-free survival of all patients was 8 months; median overall survival was 20 months. Median progression-free survival was 7 months for patients with local recurrence, 13 months for patients with distant recurrence, and 9 months for patients with both recurrence patterns (P = 0.646). Median overall survival in the 3 groups was 21 months, 20 months, and 14 months (P = 0.098). No correlation between methylguanine-deoxyribonucleic acid methyltransferase methylation status and recurrence pattern was observed. CONCLUSIONS: Despite complete resection of contrast-enhancing tumor, most recurrences occurred locally. Patients with distant tumor recurrence demonstrated increased progression-free survival. Therefore, to gain local control, we may need to shift toward a more aggressive supramarginal resection, using extensive intraoperative monitoring to avoid permanent deficits.

摘要

背景:胶质母细胞瘤的典型复发发生在局部,通常在距原发灶2厘米范围内。随着手术技术的改进,更积极的手术策略已变得可行,导致完全切除率显著提高。我们研究了这些改进是否也反映在肿瘤复发模式上。 方法:纳入标准为首次诊断为胶质母细胞瘤并接受标准辅助放化疗且经组织学证实肿瘤复发。患者根据复发模式分为:局部复发、远处复发或两种复发模式均有。数据与切除范围、分子肿瘤构型、临床状态和生存数据相关。 结果:这项单中心回顾性研究纳入了2007年至2014年期间接受治疗的97例胶质母细胞瘤患者。观察到局部、远处和合并肿瘤复发模式的患者分别为77例(79.3%)、10例(10.3%)和10例(10.3%)。所有患者的无进展生存期中位数为8个月;总生存期中位数为20个月。局部复发患者的无进展生存期中位数为7个月,远处复发患者为13个月,两种复发模式均有的患者为9个月(P = 0.646)。三组患者的总生存期中位数分别为21个月、20个月和14个月(P = 0.098)。未观察到甲基鸟嘌呤 - 脱氧核糖核酸甲基转移酶甲基化状态与复发模式之间的相关性。 结论:尽管增强肿瘤已完全切除,但大多数复发仍发生在局部。远处肿瘤复发的患者无进展生存期延长。因此,为了实现局部控制,我们可能需要转向更积极的超边缘切除,采用广泛的术中监测以避免永久性神经功能缺损。

相似文献

[1]
Recurrence Pattern Analysis of Primary Glioblastoma.

World Neurosurg. 2017-7

[2]
Glioblastoma recurrence patterns after radiation therapy with regard to the subventricular zone.

Int J Radiat Oncol Biol Phys. 2014-9-11

[3]
Analysis of Treatment Tolerance and Factors Associated with Overall Survival in Elderly Patients with Glioblastoma.

World Neurosurg. 2016-11

[4]
Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.

J Clin Oncol. 2010-5-3

[5]
Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.

Neurosurg Focus. 2014-12

[6]
Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.

Int J Radiat Oncol Biol Phys. 2010-10-6

[7]
Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide.

Radiother Oncol. 2010-9-18

[8]
The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study.

Br J Neurosurg. 2013-8

[9]
Clinical, Radiographic, and Pathologic Findings in Patients Undergoing Reoperation Following Radiation Therapy and Temozolomide for Newly Diagnosed Glioblastoma.

Am J Clin Oncol. 2017-6

[10]
Impact of oligodendroglial component in glioblastoma (GBM-O): Is the outcome favourable than glioblastoma?

Clin Neurol Neurosurg. 2015-8

引用本文的文献

[1]
Recurrence patterns and clinical outcomes in adult cerebellar glioblastoma.

Acta Neurochir (Wien). 2025-8-8

[2]
Novel radiotherapy target definition using AI-driven predictions of glioblastoma recurrence from metabolic and diffusion MRI.

NPJ Digit Med. 2025-8-7

[3]
Preoperative FLAIR images for identifying glioblastoma boundaries.

BMC Med Imaging. 2025-7-30

[4]
Identifying targetable alterations predictive of distant progression in glioblastoma patients undergoing standard therapy.

Neurooncol Adv. 2025-5-7

[5]
Reirradiation of Large or Multifocal High-Grade Gliomas With Gyroscopic Radiosurgery in Combination With Modulated Electro-Hyperthermia.

Cureus. 2025-5-5

[6]
Artificial Intelligence in Glioblastoma-Transforming Diagnosis and Treatment.

Chin Neurosurg J. 2025-6-2

[7]
Distant parenchymal recurrence during long-term use of TTFields treatment for glioblastoma.

Int J Clin Oncol. 2025-5-22

[8]
Targeting the glioblastoma resection margin with locoregional nanotechnologies.

Nat Rev Clin Oncol. 2025-5-14

[9]
Canadian Expert Consensus Recommendations for the Diagnosis and Management of Glioblastoma: Results of a Delphi Study.

Curr Oncol. 2025-4-1

[10]
A 5-Year Update on the Clinical Development of Cancer Cell-Based Vaccines for Glioblastoma Multiforme.

Pharmaceuticals (Basel). 2025-3-6

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索